Phase-2 Trial of palbociclib in adult patients with recurrent RB1-positive Glioblastoma

INTRODUCTION: Alterations in the CDK4/6 – RB signaling pathway are common causes of cell cycle dysregulation in many cancers, including glioblastoma. Palbociclib is an oral inhibitor of CDK4/6, which leads to phosphorylation of RB1 and cell-cycle arrest. We conducted a two-arm study evaluating effic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Neurooncol
Main Authors: Taylor, Jennie W., Parikh, Mili, Phillips, Joanna J., James, C. David, Molinaro, Annette M., Butowski, Nicholas A., Clarke, Jennifer L., Oberheim-Bush, Nancy Ann, Chang, Susan M., Berger, Mitchel S., Prados, Michael
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6239922/
https://ncbi.nlm.nih.gov/pubmed/30151703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2977-3
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki